What COPD Is

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable respiratory disease characterized by persistent respiratory symptoms and chronic airflow limitation caused by significant exposure to noxious gases or particles — primarily tobacco smoke (80 to 90% of cases in Brazil). The diagnosis is confirmed by spirometry: post-bronchodilator FEV1/FVC <0.70 (GOLD criterion).

COPD is a systemic disease with manifestations beyond the lung: peripheral muscle dysfunction, malnutrition, cachexia, osteoporosis, cardiovascular disease, and depression. The main feature that limits quality of life is progressive dyspnea — especially with exertion — leading to a vicious cycle of inactivity → deconditioning → worsening dyspnea → still more inactivity. Worldwide it is the third leading cause of death; in Brazil, it affects about 16 million adults.

~16 M
ADULTS WITH COPD IN BRAZIL (ESTIMATE)
3rd leading cause of death worldwide
+48 m
6MWT (6-MINUTE WALK TEST)
Mean reported in a specific RCT (BMJ Open Respir Res, 2020)
−1.2
MRC DYSPNEA SCALE
Mean reduction observed in the reference RCT
−5.3
CAT POINTS
COPD Assessment Test — data from the same RCT

The Vicious Cycle of COPD

Exertional dyspnea leads to physical inactivity, which causes muscle deconditioning (peripheral and respiratory), which worsens dyspnea at ever-smaller efforts, leading to still more inactivity. This vicious cycle is the main target of pulmonary rehabilitation — and also of acupuncture, which acts on both the perception of dyspnea and respiratory muscle function.

Conventional Treatments

COPD treatment is predominantly symptomatic and preventive. Smoking cessation is the only intervention proven to alter the FEV1 decline curve and disease progression.

PILLARS OF COPD TREATMENT

INTERVENTIONBENEFITLEVEL OF EVIDENCE
Smoking cessationThe only intervention that alters disease progressionA — absolute priority
LAMA (tiotropium, umeclidinium)Reduces dyspnea, hyperinflation, and exacerbationsA — first line in GOLD 2–4
LABA (indacaterol, formoterol)Long-acting bronchodilationA — in combination with LAMA
Pulmonary rehabilitationImproves dyspnea, 6MWT, and quality of lifeA — underused in Brazil
Home oxygen therapyReduces mortality in COPD with hypoxemiaA — resting SpO2 <88%
Vaccines (influenza, pneumococcus)Reduction of infectious exacerbationsA — mandatory

How Acupuncture Works in COPD

In COPD, acupuncture acts on three fronts: reduction of dyspnea by modulation of the respiratory reflex, improvement of respiratory muscle function, and reduction of dynamic hyperinflation through relaxation of the flattened diaphragm.

Mechanism of Action in COPD

  1. BL-13 (Feishu) + CV-17 — Modulation of the Respiratory Reflex

    BL-13 (T3) activates segmental afferents → reduces sympathetic hyperactivation of the pontine respiratory center; CV-17 modulates central perception of dyspnea via vagal TRPV1 fibers.

  2. ST-36 + ST-40 — Respiratory Muscle Strength

    Improvement in strength and endurance of accessory respiratory muscles (scalenes, sternocleidomastoid); ST-40 (Fenglong) — the "phlegm-transformation" point — reduces mucus secretion and improves expectoration.

  3. KI-3 (Taixi) — Renal Foundation of Respiration

    In Chinese medicine, "the Kidney governs the grasping of respiratory Qi"; in modern terms, KI-3 improves the response to exercise by regulating tissue O2 saturation and peripheral muscle mitochondrial efficiency.

  4. Reduction of Dynamic Hyperinflation

    Relaxation of the flattened diaphragm and accessory intercostal muscles → improved tidal volume → reduction of the functional residual capacity that is pathologically elevated in severe COPD.

  5. TRPV1 (Capsaicin Receptor) Modulation

    TRPV1 receptors in the airways mediate the perception of dyspnea and cough. Acupuncture reduces sensitization of these receptors → reduction of the subjective sensation of breathlessness independent of objective lung function.

Scientific Evidence

BMJ Open Respir Res 2020 — RCT (n=147)

147 patients with COPD GOLD 2–3 randomized to real acupuncture (BL-13+ST-36+CV-17+KI-3) versus sham for 12 weeks. Results:6MWT (6-Minute Walk Test) +48 meters in the acupuncture group vs. +12 m in sham (p<0.001). MRC dyspnea scale −1.2 vs. −0.4. CAT (COPD Assessment Test) −5.3 vs. −2.1. SpO2 on exertion +2.1% in the acupuncture group.

J Altern Complement Med 2019 — Meta-analysis (12 RCTs, n=847)

Meta-analysis of 12 RCTs in COPD GOLD II–IV. MRC dyspnea score:−1.3 in the acupuncture group vs. controls (95% CI −1.9 to −0.7). SGRQ (St. George's Respiratory Questionnaire) improvement of 8.2 points (minimum clinically important difference = 4 points). No significant difference in FEV1 or FVC — confirming that the benefit is in the perception of dyspnea and function, not in spirometry.

Modern Approach: Medical Acupuncture in COPD

CLINICAL PROTOCOL IN COPD

PARAMETERSPECIFICATIONRATIONALE
Main pointsBL-13 + ST-36 + CV-17Pulmonary + systemic + central respiratory
Auxiliary pointsKI-3 + ST-40 + LU-7Renal foundation + phlegm + lung meridian
Electroacupuncture2 Hz on BL-13+ST-36Respiratory muscle strength
Frequency2 sessions/week for 12 weeks6MWT every 4 weeks for monitoring
Goal in mild-moderate COPDIncrease 6MWT and reduce MRCEnable pulmonary rehabilitation
Goal in severe COPDReduce dyspnea and improve CATQuality of life as primary outcome

When to See a Medical Acupuncturist

Priority Indications

  • COPD GOLD 2–3 with significant functional limitation
  • Dyspnea MRC ≥3 — preventing pulmonary rehabilitation
  • Very low quality of life (CAT >20)
  • Concurrent smoking cessation
  • Frequent exacerbations with anxiety component

Requires Prior Evaluation

  • Recent spirometry for GOLD staging
  • Resting and exertional SpO2 before starting
  • COPD GOLD 4 with hypoxemia: home O2 takes priority
  • Acute exacerbation: antibiotic + systemic corticosteroid first

Frequently Asked Questions

FREQUENTLY ASKED QUESTIONS · 05

Frequently Asked Questions

No. COPD causes irreversible alveolar destruction (emphysema) and airway remodeling that is not reversed by any current treatment. Acupuncture improves symptoms, exercise capacity, and quality of life — but does not restore the destroyed lung tissue. Spirometry rarely changes; the outcomes are functional.

No. LAMA/LABA bronchodilators are the pharmacological foundation of GOLD 2–4 treatment and should not be replaced. Acupuncture acts as a complementary therapy — it can contribute to the control of dyspnea and functional capacity, always coordinated with the pulmonologist who manages the bronchodilator treatment.

The BMJ Open study (2020) observed significant improvement in 6MWT and CAT after 12 weeks (24 sessions). Earlier improvement in dyspnea is typically reported starting from the 4th to 6th session. Monitoring with 6MWT every 4 weeks allows objective assessment of response.

It is not indicated as treatment for acute exacerbations — which require bronchodilators, systemic corticosteroids, and antibiotics when bacterial. After resolution of the exacerbation, the acupuncture cycle can be restarted for rehabilitation and prevention of new exacerbations.

Yes. Home oxygen and acupuncture are compatible. In GOLD 4 patients with hypoxemia, acupuncture focuses on quality of life and dyspnea reduction, not significant functional improvement (which is limited by disease severity). The pulmonologist should coordinate all interventions.

Related Articles